Topic Review
Molecular Radiobiology with Liquid Biopsies
Using liquid biopsy techniques including ctDNA analysis as tools to study radiobiology in patients with cancer.
  • 648
  • 29 Oct 2021
Topic Review
Triple-Negative Breast Cancer Molecular Subtyping
Breast cancer (BC) is the most common malignancy affecting women. It is a highly heterogeneous disease broadly defined by the differential expression of cell surface receptors. In the United States, triple negative breast cancer (TNBC) represents 15 to 20% of all BC. When compared with other subtypes of BC, TNBC tends to present in younger women, and has a higher mortality rate of 40% in advanced stages within the first 5 years after diagnosis. TNBC has historically had limited treatment options when compared to other types of BC.
  • 648
  • 09 Mar 2022
Topic Review
Cancer Therapy (Radiation)-Induced Immune Modulation
Cancer therapy-related cardiopulmonary dysfunction (CTRCPD) is one of the most undesirable side effects of cancer therapy and leads to limitations to cancer treatment. Chemoradiation therapy or immunotherapy promote acute and chronic cardiopulmonary damage by inducing reactive oxygen species, DNA damage, inflammation, fibrosis, deregulation of cellular immunity, cardiopulmonary failure, and non-malignant related deaths among cancer-free patients who received cancer therapy. The efficacy of the radiation depends on the degree of DNA damage, which results in cancer cell death.
  • 648
  • 14 Sep 2022
Topic Review
Radiotherapy Induced Immunogenic Cell Death
The immunogenic cell death (ICD) is defined as a regulated cell death able to induce an adaptive immunity. It depends on different parameters including sufficient antigenicity, adjuvanticity and favorable microenvironment conditions. Radiation therapy (RT), a pillar of modern cancer treatment, is being used in many tumor types in curative, (neo) adjuvant, as well as metastatic settings. The anti-tumor effects of RT have been traditionally attributed to the mitotic cell death resulting from the DNA damages triggered by the release of reactive oxygen species. Recent evidence sug-gests that RT may also exert its anti-tumor effect by recruiting tumor-specific immunity. RT is able to induce the release of tumor antigens, to act as an immune adjuvant and thus to synergize with the anti-tumor immunity. The advent of new efficient immunotherapeutic agents, such as im-mune checkpoint inhibitors (ICI), in multiple tumor types sheds new light on the opportunity of combining RT and ICI.
  • 647
  • 16 Mar 2021
Topic Review
Breast Cancer Biomarkers From Peripheral Blood Cells
While tissue-specific biomarkers, including immune-cell infiltration of the tumor, atypical cells, changes in tumor gene expression, and other malignant changes can serve as reliable cancer biomarkers, they have certain limitations. For instance, the invasiveness of biopsy acquisition makes tissue-specific biomarkers ill-fitted for the real-time monitoring of treatment response. Additionally, while tumor-infiltrating lymphocytes (TILs) may be powerful prognostic biomarkers and have significant predictive value in identifying patients with the highest likelihood of responding to therapy, they are not useful for the early detection of cancer or for cancer screening in people with no symptoms. Less invasive and more easily accessible methods of biological sample acquisition, such as blood collection, can make early detection more feasible and may increase acceptance among patients, thereby leading to potentially faster diagnosis. Need to focus on circulating blood cell transcriptome as a source of breast cancer (BC) biomarkers.
  • 647
  • 12 Apr 2022
Topic Review
Lipogenesis and Breast Cancer
In recent years, lipid metabolism has gained greater attention in several diseases including cancer. Dysregulation of fatty acid metabolism is a key component in breast cancer malignant transformation. In particular, de novo lipogenesis provides the substrate required by the proliferating tumor cells to maintain their membrane composition and energetic functions during enhanced growth. However, it appears that not all breast cancer subtypes depend on de novo lipogenesis for fatty acid replenishment. Indeed, while breast cancer luminal subtypes rely on de novo lipogenesis, the basal-like receptor-negative subtype overexpresses genes involved in the utilization of exogenous-derived fatty acids, in the synthesis of triacylglycerols and lipid droplets, and fatty acid oxidation. These metabolic differences are specifically associated with genomic and proteomic changes that can perturb lipogenic enzymes and related pathways. This behavior is further supported by the observation that breast cancer patients can be stratified according to their molecular profiles. Moreover, the discovery that extracellular vesicles act as a vehicle of metabolic enzymes and oncometabolites may provide the opportunity to noninvasively define tumor metabolic signature. 
  • 647
  • 13 Apr 2021
Topic Review
Urological Melanoma
Melanoma is reported as the 19th most common cancer worldwide, with estimated age-standardized incidence rates of 2.8–3.1 per 100,000. Although the origin is most frequently cutaneous, mucosal melanoma has been described several times in literature, and despite its rarity (only 1% of all melanomas), increasing attention is being paid to this disease form. Within this subgroup, melanomas of the uropoetic apparatus are a rarity among rarities. Indeed, less than 50 cases of primary melanoma originating from the urinary bladder have been described, and even less originating from the kidney, renal pelvis and urethra.
  • 646
  • 08 Sep 2021
Topic Review
Differential Co-Expression Analyses
Biological systems respond to perturbations through the rewiring of molecular interactions, organised in gene regulatory networks (GRNs). Among these, the increasingly high availability of transcriptomic data makes gene co-expression networks the most exploited ones. Differential co-expression networks are useful tools to identify changes in response to an external perturbation, such as mutations predisposing to cancer development, and leading to changes in the activity of gene expression regulators or signalling. They can help explain the robustness of cancer cells to perturbations and identify promising candidates for targeted therapy, moreover providing higher specificity with respect to standard co-expression methods.
  • 645
  • 18 Dec 2020
Topic Review
Protein Kinase C in NSCLC
Despite significant advances, targeted therapy is greatly limited by resistance acquisition, which emerges in nearly all patients receiving treatment. As a result, identifying the molecular modulators of resistance is of great interest. Recent work has implicated protein kinase C (PKC) isozymes as mediators of drug resistance in non-small cell lung cancer (NSCLC). Importantly, previous findings on PKC have implicated this family of enzymes in both tumor-promotive and tumor-suppressive biology in various tissues. Here, we review the biological role of PKC isozymes in NSCLC through extensive analysis of cell-line-based studies to better understand the rationale for PKC inhibition.
  • 645
  • 22 Sep 2021
Topic Review
CTLA-4
Immune checkpoint inhibitors (ICIs) have obtained durable responses in many cancers, making it possible to foresee their potential in improving the health of cancer patients. However, immunotherapies are limited at the moment to a minority of patients and there is a need for a better understanding of the basic molecular mechanisms and functions of pivotal immune regulatory molecules. Immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and regulatory T (Treg) cells play pivotal roles in hindering the anticancer immunity. Treg cells suppress antigen-presenting cells (APCs) by depleting immune stimulating cytokines, producing immunosuppressive cytokines and constitutively expressing CTLA-4. CTLA-4 molecules bind with higher affinity to CD80 and CD86 than CD28 and act as competitive inhibitors of CD28 in APCs. The purpose of this review is to summarize state-of-the-art understanding of the molecular mechanisms underlining CTLA-4 immune regulation and the correlation of ICI response with CTLA-4 expression in Treg cells from preclinical and clinical studies for possibly improving CTLA-4-based immunotherapies, while highlighting the knowledge gap. 
  • 645
  • 13 Apr 2021
Topic Review
MicroRNAs in Hepatocellular Carcinoma
This study examines the roles of microRNAs (miRNAs) in hepatocellular carcinoma (HCC), one of the most dangerous and common cancers globally. HCC has been widely studied, and its oncogenesis and progression is well understood. Although many therapeutic approaches have been developed, the prognosis for HCC, in terms of late diagnosis, resistance to chemotherapy, tumor recurrence, and metastasis, remains poor. Malignancy causes miRNAs to become deregulated, with widespread consequences in terms of cancer development and prognosis; miRNAs are therefore key therapeutic targets. This comprehensive review summarizes the roles of miRNAs in HCC, and examines their mechanisms of action. We believe that this review makes a significant contribution to the literature because we present an up-to-date and detailed overview of the involvement of miRNAs in HCC, and of their potential as therapeutic targets and biomarkers.
  • 644
  • 13 Dec 2020
Topic Review
Contribution of LAT1-4F2hc
LAT1-4F2hc complex is an important amino acid transporter. It mainly transports specific amino acids through the cell membrane, provides nutrition for cells, and participates in a variety of metabolic pathways. LAT1 plays a role in transporting essential amino acids including leucine, which regulates the mTOR signaling pathway. 
  • 644
  • 26 Jan 2022
Topic Review
New Subtypes of B-ALL Introduced in WHO-HAEM5
B-ALL with iAMP21 and B-ALL with Ph-like features were upgraded from provisional to definite subtypes of ALL. B-ALL with TCF3::HLF fusion was included as a new subtype of B-ALL; all three of these subtypes have been discussed above. This research briefly describes the other new genetic subtypes of B-ALL in WHO-HAEM5.
  • 644
  • 14 Aug 2023
Topic Review
Tumor Suppressor Protein p53
Tumor suppressor 53 (p53) is a multifunctional protein that regulates cell cycle, DNA repair, apoptosis and metabolic pathways. In colorectal cancer (CRC), mutations of the gene occur in 60% of patients and are associated with a more aggressive tumor phenotype and resistance to anti-cancer therapy. In addition, inhibitor of apoptosis (IAP) proteins are distinguished biomarkers overexpressed in CRC that impact on a diverse set of signaling pathways associated with the regulation of apoptosis/autophagy, cell migration, cell cycle and DNA damage response. As these mechanisms are further firmly controlled by p53, a transcriptional and post-translational regulation of IAPs by p53 is expected to occur in cancer cells. Here, we aim to review the molecular regulatory mechanisms between IAPs and p53 and discuss the therapeutic potential of targeting their interrelationship by multimodal treatment options.
  • 644
  • 25 Jun 2021
Topic Review
Polyphenols in Leukaemia
Leukaemia is a malignant disease of the blood. Current treatments for leukaemia are associated with serious side-effects. Here we discuss the potential therapeutic use of polyphenols in leukaemia. We outline the molecular mechanism of action of polyphenol in leukaemia cell lines, and discuss the pharmacological properties of polyphenols, including their anti-inflammatory, antioxidant, anti-proliferative, and anti-tumour activities, and suggest that polyphenols are potent natural agents that can be useful therapeutically; and discuss why data on bioavailability, toxicity and metabolism is essential to evaluate their clinical use. 
  • 643
  • 22 Sep 2021
Topic Review
Hepatocellular Carcinoma Heterogeneity
Tumor heterogeneity in liver cancer is a major contributor to the high lethality rate found in patients suffering from this disease. The therapeutic outcomes are drastically affected by this heterogeneity, which complicates patient stratification and response prediction. 
  • 642
  • 03 Jun 2021
Topic Review
MicroRNA Biomarkers in Prostate Cancer by Ultrasound-Based Identification
MiRNAs are ~22-nucleotide long noncoding sequences of RNA that are located across the genome, within an intron or untranslated region (UTR) of a coding gene. Pri-miRNAs are transcribed from their genes in longer primary transcripts which are processed by two RNase III proteins—Drosha and Dicer—to form a functional miRISC complex that binds to the 3′ UTR of target mRNAs and induces their degradation and translational repression . miRNAs were found to be highly stable in blood and other body fluids, where they circulate in a cell-free form, bound to other proteins, lipids, or lipoprotein or encapsulated in exosomes. The development of specific high-throughput detection methods allowing miRNA detection in extracellular fluids, besides the fact that profiles of miRNAs were shown to be either downregulated or overexpressed across several cancer types compared to normal counterparts, has paved the way for serum miRNAs to be developed as biomarkers for early detection and monitoring of tumor evolution. However, significant challenges remain, such as the low concentration of miRNAs released in the blood, especially in early-stage disease, and the difficult identification of biomarker release sites.
  • 642
  • 12 Nov 2021
Topic Review
Vaginal Cancer
According to the International Federation of Gynecology and Obstetrics (FIGO), vaginal cancer is strictly defined as cancer found in the vagina without clinical or histologic evidence of cervical or vulvar cancer, or a prior history of these cancers within 5 years. Primary vaginal cancer is a rare gynecologic malignancy. Given the rarity of the disease, standardized approaches to management are limited, and a great variety of therapeutic conditions are endorsed. 
  • 642
  • 12 Aug 2022
Topic Review
Design Strategy for Breast Cancer Vaccine
Breast cancer has been recorded as the type of cancer that causes the highest mortality in women due to its high incidence. Given the devastating implications of the disease and the growing number of cases, many scientists and research organizations have dedicated their efforts to the fight against breast cancer. Vaccines are an upcoming medical intervention for breast cancer. By targeting the tumor antigen, cancer vaccines can be designed to train the immune system to recognize tumor cells.
  • 642
  • 10 Jan 2023
Topic Review
Pineal Gland Tumors
Pineal gland neoplasms are tumors with different and variable morphological, histological, and radiological characteristics and, consequently different diagnosis and management. Pineal tumors, are divided into germ cell tumors, pineal parenchymal tumors and tumors that derive from adjacent structures.
  • 641
  • 21 Jul 2021
  • Page
  • of
  • 128
ScholarVision Creations